The MONARCH-1 trial studied abemaciclib, a CDK4/6 inhibitor, in 132 patients with refractory HR+/HER2− breast cancer and demonstrated an ORR of 19.7%, mPFS of 6.0 months, and mOS of 17.7 months [32]. Here, CDK4 is linked to breast carcinoma.